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Occurrence frequency
• United States population
- Estimated frequency of approximately 1 in 220,000 live births
• The Mennonite population (United States)
- Estimated frequency of approximately 1 in 380 live births
(The much higher frequency among the Mennonites is due to the founder effect, 
i.e., when inbreeding in isolated groups results in a small gene pool with 
persistence of genes/mutation)
• A child may have increased risk of MSUD due to both parents being carriers of a 
spontaneous/random mutation, of Mennonite lineage, or both
Genetics
• Autosomal recessive disorder (i.e., two mutant copies needed to manifest disease)
• The mutation could be in one of three genes that code for the branched chain 𝛼-keto-acid 
dehydrogenase complex (BCKD), which breaks down three branched chain amino acids


















MSUD associated with a 
defect in protein 
utilization
* Each exemplar shown above was chosen because of its
representative value to the respective group but note that the
depicted item is not entirely devoid of the two other food groups
Nature of the problem in MSUD
Digital image retrieved Nov 7, 2020 from 
https://killcliff.com/blogs/hpc/do-you-need-bcaas
In MSUD, defective BCKD enzyme cannot 
break down these three essential* amino acids
Amino acids are the 
building blocks of proteins
* Essential refers to those amino acids that the body cannot make 
and must therefore be obtained from the diet
Digital image retrieved Nov 7, 2020 from 
https://nickrauh.wordpress.com/2014/03/20/biochemistry/
• Defective BCKD enzyme – variants 
of MSUD have varying severity of 
deficits in activity
• Build-up of branched chain amino 
acids and 𝛼-keto acids (reflected in 
high levels in blood and urine)
• Stools, urine, sweat, and earwax 
that smells of maple syrup, the 
odor associated with 𝛼-keto acids 
Biochemical features
Branched Chain Amino Acids (BCAAs)
𝛼-keto acids
Symptoms
• Symptoms can appear starting about 3 days after birth as the toxic metabolites accumulate; 
symptoms include:
• Bodily fluids smell of maple syrup
• Poor feeding, vomiting, loss of appetite, irritability
• Tiredness and weakness
• Poor muscle tone (”floppy”) or stiffness of muscles
• Abnormal muscle movements
• Developmental delay
• Seizures and convulsions leading to respiratory failure/coma




- May result in a false negative due to
lack of adequate time for measurable 
accumulation of toxic metabolites
• Post birth/toddler 
- Analysis of plasma, urine, and white 
blood cells, symptom assessment
- Amino acid and BCKD enzyme testing 
to check for elevated levels
Newborn screening
Digital image retrieved Nov 07, 2020 from 
https://www.af.mil/News/Photos/igphoto/2000419731/
Prenatal diagnosis
If a fetus is predisposed to MSUD (based on either 
family history or previously affected child), two 
prenatal diagnosis methods can be used for 
testing of BCKD enzyme activity:
• Chorionic villus sampling: performed at 
11-14 weeks; biopsy of cells from mother's 
placenta for testing; low risk of amniotic 
leakage or of infection
• Amniocentesis: performed at 15-20 weeks; 
amniotic fluid is removed and tested; some 
risk of amniotic leakage and infection
Amniocentesis




• Strict high-calorie diet to prevent breakdown of body’s energy 
stores and weight loss
• Limit intake of leucine, isoleucine, and valine (present in all 
proteins); intake is limited for infants by specialized formulas
- Underestimating intake may result in development of symptoms
• Frequently monitor levels of BCAAs in the blood (twice a 
week for infants and weekly for older children/adults)
• Liver transplant to restore functional enzyme; albeit a 
possibility, this approach has its own risks, and it will not 














* An individual with MSUD must limit dietary intake 
of these food types to avoid a metabolic crisis
Prognosis
• Maple Syrup Urine Disease is managed through strict diet
- BCAA-free formula for infants provides necessary dietary 
sustenance without harmful BCAAs
- BCAAs are supplemented into the diet in very low amounts
- However, even with strict diet control, an individual is still at 
high risk for metabolic attack
• An affected individual can grow into adulthood with normal 
development 
• Symptoms will vary in intensity based on the relative activity of 
the enzyme in affected individuals
MSUD Formula





MSUD Family Support Group
• Access to current, relevant MSUD research
• Network of MSUD-specific dieticians, physicians, and facilities
Organic Acidemia Association
• Information on diagnosis procedures
• Facebook support group, conferences, and research fundraising
National Organization for Rare Disorders 
• Patient and family advocacy
• Information for financial assistance and research opportunities
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